Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14208874 | 1.00 | POLB (0.36) | POLBBRD4SYK | |
| SCHEMBL12776916 | 0.89 | POLB (0.38) | POLBBRD4SYK | |
| SCHEMBL12201463 | 0.81 | SYK (0.38) | BRD4SYK | |
| SCHEMBL5030437 | 0.78 | POLB (0.41) | POLBBRD4 | |
| SCHEMBL14208872 | 0.78 | BRD4 (0.33) | BRD4SYK | |
| SCHEMBL1490695 | 0.76 | STK17B (0.44) | POLBBRD4 | |
| SCHEMBL6097448 | 0.76 | STK17B (0.47) | POLBBRD4 | |
| SCHEMBL4300592 | 0.75 | GAA (0.41) | POLB | |
| SCHEMBL5334549 | 0.75 | POLB (0.39) | POLBBRD4 | |
| SCHEMBL5027847 | 0.74 | LATS1 (0.37) | POLBBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034938-B2 | Imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a CH( R1) group in the fused ring at 1-position of imidazo ring; modulate immune response, by induction of cytokine biosynthesis or other mechanism | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-10-11 | — | — | US | disclosed |
| US-20080085895-A1 | Substituted Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds | 3M INNOVATIVE PROPERTIES COMPANY | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085895-A1 | Substituted Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds | IFNG, IL4, IFNAR1 | POLB 3754/4885BRD4 375/4885SYK 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.